These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 16650995

  • 1. 2D QSAR of PPARgamma agonist binding and transactivation.
    Rücker C, Scarsi M, Meringer M.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5178-95. PubMed ID: 16650995
    [Abstract] [Full Text] [Related]

  • 2. Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics.
    Giaginis C, Theocharis S, Tsantili-Kakoulidou A.
    Chem Biol Drug Des; 2008 Oct 01; 72(4):257-64. PubMed ID: 18793305
    [Abstract] [Full Text] [Related]

  • 3. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
    Dong X, Zhang Z, Wen R, Shen J, Shen X, Jiang H.
    Bioorg Med Chem Lett; 2006 Nov 15; 16(22):5913-6. PubMed ID: 17010604
    [Abstract] [Full Text] [Related]

  • 4. DASH: a novel analysis method for molecular dynamics simulation data. Analysis of ligands of PPAR-gamma.
    Salt DW, Hudson BD, Banting L, Ellis MJ, Ford MG.
    J Med Chem; 2005 May 05; 48(9):3214-20. PubMed ID: 15857127
    [Abstract] [Full Text] [Related]

  • 5. 'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists.
    Sundriyal S, Bharatam PV.
    Eur J Med Chem; 2009 Jan 05; 44(1):42-53. PubMed ID: 18448203
    [Abstract] [Full Text] [Related]

  • 6. Predicting the toxic potential of drugs and chemicals in silico: a model for the peroxisome proliferator-activated receptor gamma (PPAR gamma).
    Vedani A, Descloux AV, Spreafico M, Ernst B.
    Toxicol Lett; 2007 Aug 30; 173(1):17-23. PubMed ID: 17643875
    [Abstract] [Full Text] [Related]

  • 7. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Sheu SH, Kaya T, Waxman DJ, Vajda S.
    Biochemistry; 2005 Feb 01; 44(4):1193-209. PubMed ID: 15667213
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship.
    Ohashi M, Oyama T, Nakagome I, Satoh M, Nishio Y, Nobusada H, Hirono S, Morikawa K, Hashimoto Y, Miyachi H.
    J Med Chem; 2011 Jan 13; 54(1):331-41. PubMed ID: 21128600
    [Abstract] [Full Text] [Related]

  • 9. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
    Guasch L, Sala E, Valls C, Mulero M, Pujadas G, Garcia-Vallvé S.
    J Mol Graph Model; 2012 Jun 13; 36():1-9. PubMed ID: 22503857
    [Abstract] [Full Text] [Related]

  • 10. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
    Peng YH, Coumar MS, Leou JS, Wu JS, Shiao HY, Lin CH, Lin WH, Lien TW, Chen X, Hsu JT, Chao YS, Huang CF, Lyu PC, Hsieh HP, Wu SY.
    ChemMedChem; 2010 Oct 04; 5(10):1707-16. PubMed ID: 20734309
    [Abstract] [Full Text] [Related]

  • 11. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
    Oloff S, Mailman RB, Tropsha A.
    J Med Chem; 2005 Nov 17; 48(23):7322-32. PubMed ID: 16279792
    [Abstract] [Full Text] [Related]

  • 12. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G, Saxena AK.
    J Chem Inf Model; 2006 Nov 17; 46(6):2579-90. PubMed ID: 17125198
    [Abstract] [Full Text] [Related]

  • 13. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y, Coales SJ, Morrow JA, Molnar KS, Tuske SJ, Southern MR, Griffin PR.
    Protein Sci; 2006 Aug 17; 15(8):1883-92. PubMed ID: 16823031
    [Abstract] [Full Text] [Related]

  • 14. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, Kamiya N, Jingami H, Morikawa K.
    J Mol Biol; 2009 Jan 09; 385(1):188-99. PubMed ID: 18977231
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
    Mahindroo N, Wang CC, Liao CC, Huang CF, Lu IL, Lien TW, Peng YH, Huang WJ, Lin YT, Hsu MC, Lin CH, Tsai CH, Hsu JT, Chen X, Lyu PC, Chao YS, Wu SY, Hsieh HP.
    J Med Chem; 2006 Feb 09; 49(3):1212-6. PubMed ID: 16451087
    [Abstract] [Full Text] [Related]

  • 17. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 18. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.
    Guasch L, Sala E, Valls C, Blay M, Mulero M, Arola L, Pujadas G, Garcia-Vallvé S.
    J Comput Aided Mol Des; 2011 Aug 14; 25(8):717-28. PubMed ID: 21691811
    [Abstract] [Full Text] [Related]

  • 19. Prediction and mechanistic interpretation of human oral drug absorption using MI-QSAR analysis.
    Iyer M, Tseng YJ, Senese CL, Liu J, Hopfinger AJ.
    Mol Pharm; 2007 Aug 14; 4(2):218-31. PubMed ID: 17397237
    [Abstract] [Full Text] [Related]

  • 20. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA, Sylte I.
    Chem Biol Drug Des; 2008 Jul 14; 72(1):50-7. PubMed ID: 18554251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.